Search hospitals > Florida > Orlando
Florida Hospital Cancer Institute
Claim this profileOrlando, Florida 32804
Global Leader in Lung Cancer
Global Leader in Leukemia
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Breast Cancer
Conducts research for Lymphoma
215 reported clinical trials
8 medical researchers
Summary
Florida Hospital Cancer Institute is a medical facility located in Orlando, Florida. This center is recognized for care of Lung Cancer, Leukemia, Non-Small Cell Lung Cancer, Breast Cancer, Lymphoma and other specialties. Florida Hospital Cancer Institute is involved with conducting 215 clinical trials across 178 conditions. There are 8 research doctors associated with this hospital, such as Carlos Alemany, Mohamedtaki A. Tejani, Guru P Sonpavde, MD, and Robert Holloway, MD.Area of expertise
1Lung Cancer
Global LeaderStage IV
metastatic
locally advanced
2Leukemia
Global LeaderFLT3 positive
Top PIs
Carlos AlemanyAdventHealth Orlando4 years of reported clinical research
Studies Breast Cancer
Studies Cancer
21 reported clinical trials
58 drugs studied
Mohamedtaki A. TejaniAdventHealth Orlando2 years of reported clinical research
Studies Adenocarcinoma
Studies Colorectal Cancer
17 reported clinical trials
35 drugs studied
Guru P Sonpavde, MDDana Farber Cancer Institute3 years of reported clinical research
Studies Cancer
Studies Bladder Cancer
14 reported clinical trials
21 drugs studied
Robert Holloway, MDAdventHealth Cancer Institute2 years of reported clinical research
Studies Ovarian Cancer
Studies Ovarian Tumors
11 reported clinical trials
23 drugs studied
Clinical Trials running at Florida Hospital Cancer Institute
Ovarian Cancer
Non-Small Cell Lung Cancer
Lung Cancer
Cancer
Pancreatic Cancer
Non-Hodgkin's Lymphoma
Small Cell Lung Cancer
Solid Tumors
Gastroesophageal Junction Adenocarcinoma
Stomach Cancer
Olvi-Vec + Chemotherapy
for Ovarian Cancer
The OnPrime study is a multi-center, randomized open-label phase 3 study evaluating the safety and efficacy of Olvi-Vec followed by platinum-doublet chemotherapy and bevacizumab compared to the Active Comparator Arm with Physician's Choice of chemotherapy and bevacizumab in women diagnosed with platinum-resistant/refractory ovarian cancer (includes fallopian tube cancer and primary peritoneal cancer). This Phase III trial builds on the efficacy and safety data reported in the previous Phase II VIRO-15 trial with promising objective response rate and progression-free survival observed in heavily pre-treated patients with platinum-resistant/refractory ovarian cancer. The phase II results also showed that the intra-peritoneal route of delivery was efficient in generating tumor cell killing and immune activation, and led to clinical reversal of platinum-resistance or refractoriness in this difficult-to-treat patient population.
Recruiting2 awards Phase 313 criteria
ONC-392 + Pembrolizumab
for Non-Small Cell Lung Cancer
This trial tests ONC-392, an antibody that helps the immune system fight cancer, in patients with advanced or spreading tumors who haven't responded to other treatments. It works by blocking a protein that usually keeps immune responses in check, making it easier for the body to attack cancer cells.
Recruiting1 award Phase 1 & 212 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Florida Hospital Cancer Institute?
Florida Hospital Cancer Institute is a medical facility located in Orlando, Florida. This center is recognized for care of Lung Cancer, Leukemia, Non-Small Cell Lung Cancer, Breast Cancer, Lymphoma and other specialties. Florida Hospital Cancer Institute is involved with conducting 215 clinical trials across 178 conditions. There are 8 research doctors associated with this hospital, such as Carlos Alemany, Mohamedtaki A. Tejani, Guru P Sonpavde, MD, and Robert Holloway, MD.